Geneva, Switzerland: The first European Clinical Practice Guidelines (CPGs) for the diagnosis and management of Wilson's disease are published today by the European Association for the Study of the ...

Since the observation that injections of 2,3-dimer-captopropanol (BAL) benefit the neurologic symptoms 8 and, in 1 case, 9 may have benefited a patient in the "preneurologic" stage, it is of the ...

Wilson’s disease is a rare genetic disorder in which copper accumulates in the body. It usually affects the liver and the brain, but can also involve the kidneys, the heart and the eyes. Symptoms are ...

Wilson’s disease is an autosomal recessive disorder caused by ATP7B mutations, leading to copper accumulation in the liver, ...

Researchers report that they have conducted promising preclinical experiments on a compound that could be used to treat Wilson's disease and possibly other disorders -- including certain types of ...

Please provide your email address to receive an email when new articles are posted on . Orphalan announced FDA approval of Cuvrior for the treatment of adults with stable Wilson’s disease who are ...

Ultragenyx Pharmaceutical Inc. RARE announced that the FDA has cleared the Investigational New Drug (IND) application for UX701, being evaluated for the treatment of Wilson Disease. Wilson disease is ...

The Hah1 metallochaperone protein is implicated in copper delivery to the Menkes and Wilson disease proteins. Hah1 and the N-termini of its target proteins belong to a family of metal binding domains ...

Wilson's Disease, also known as hepatolenticular degeneration, is a genetic disease involving the inability of the body to remove excess copper. Small amounts of copper are essential for normal living ...